Stock Track | Edwards Lifesciences Soars 7.54% After-Hours on Strong Q2 Results and Raised Guidance

Stock Track

Jul 25, 2025

Edwards Lifesciences Corporation (EW) saw its stock price surge 7.54% in after-hours trading on Thursday, following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year guidance.

The medical technology company reported a robust 11.9% increase in Q2 sales, reaching $1.53 billion, surpassing the analysts' estimate of $1.49 billion. Adjusted earnings per share (EPS) came in at $0.67, beating the consensus estimate of $0.62. The company's performance was driven by strong growth across its product lines, with Transcatheter Aortic Valve Replacement (TAVR) sales rising 8.9% and Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reaching $134.5 million.

In light of these strong results, Edwards Lifesciences raised its full-year 2025 guidance. The company now expects total sales growth of 9% to 10%, projecting revenues between $5.9 billion and $6.1 billion. Additionally, the company adjusted its underlying growth rate guidance for TAVR to 6% to 7%. The positive outlook, coupled with the Q2 earnings beat, appears to have fueled investor optimism, leading to the significant after-hours stock price increase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1125630328"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125630328\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125630328?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-25 04:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125630328","market":"hk","top_or_hot":-1,"title":"Stock Track | Edwards Lifesciences Soars 7.54% After-Hours on Strong Q2 Results and Raised Guidance","media":"Stock Track","content":"<p>Edwards Lifesciences Corporation (EW) saw its stock price surge 7.54% in after-hours trading on Thursday, following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year guidance.</p>\n\n<p>The medical technology company reported a robust 11.9% increase in Q2 sales, reaching $1.53 billion, surpassing the analysts' estimate of $1.49 billion. Adjusted earnings per share (EPS) came in at $0.67, beating the consensus estimate of $0.62. The company's performance was driven by strong growth across its product lines, with Transcatheter Aortic Valve Replacement (TAVR) sales rising 8.9% and Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reaching $134.5 million.</p>\n\n<p>In light of these strong results, Edwards Lifesciences raised its full-year 2025 guidance. The company now expects total sales growth of 9% to 10%, projecting revenues between $5.9 billion and $6.1 billion. Additionally, the company adjusted its underlying growth rate guidance for TAVR to 6% to 7%. The positive outlook, coupled with the Q2 earnings beat, appears to have fueled investor optimism, leading to the significant after-hours stock price increase.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Edwards Lifesciences Soars 7.54% After-Hours on Strong Q2 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Edwards Lifesciences Soars 7.54% After-Hours on Strong Q2 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-07-25 04:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Edwards Lifesciences Corporation (EW) saw its stock price surge 7.54% in after-hours trading on Thursday, following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year guidance.</p>\n\n<p>The medical technology company reported a robust 11.9% increase in Q2 sales, reaching $1.53 billion, surpassing the analysts' estimate of $1.49 billion. Adjusted earnings per share (EPS) came in at $0.67, beating the consensus estimate of $0.62. The company's performance was driven by strong growth across its product lines, with Transcatheter Aortic Valve Replacement (TAVR) sales rising 8.9% and Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reaching $134.5 million.</p>\n\n<p>In light of these strong results, Edwards Lifesciences raised its full-year 2025 guidance. The company now expects total sales growth of 9% to 10%, projecting revenues between $5.9 billion and $6.1 billion. Additionally, the company adjusted its underlying growth rate guidance for TAVR to 6% to 7%. The positive outlook, coupled with the Q2 earnings beat, appears to have fueled investor optimism, leading to the significant after-hours stock price increase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EW","symbol_name":"爱德华兹","start_time":0,"source_url":"","article_id":"1125630328","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125630328","pubTimestamp":1753389394,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Edwards Lifesciences Corporation (EW) saw its stock price surge 7.54% in after-hours trading on Thursday, following the release of its impressive second-quarter 2025 financial results and an upward...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EW":"爱德华兹"},"translate_title":"个股追踪|Edwards Lifesciences盘后大涨7.54%，Q2业绩强劲，指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EW":1},"content_text":"Edwards Lifesciences Corporation (EW) saw its stock price surge 7.54% in after-hours trading on Thursday, following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year guidance.\nThe medical technology company reported a robust 11.9% increase in Q2 sales, reaching $1.53 billion, surpassing the analysts' estimate of $1.49 billion. Adjusted earnings per share (EPS) came in at $0.67, beating the consensus estimate of $0.62. The company's performance was driven by strong growth across its product lines, with Transcatheter Aortic Valve Replacement (TAVR) sales rising 8.9% and Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reaching $134.5 million.\nIn light of these strong results, Edwards Lifesciences raised its full-year 2025 guidance. The company now expects total sales growth of 9% to 10%, projecting revenues between $5.9 billion and $6.1 billion. Additionally, the company adjusted its underlying growth rate guidance for TAVR to 6% to 7%. The positive outlook, coupled with the Q2 earnings beat, appears to have fueled investor optimism, leading to the significant after-hours stock price increase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}